Following a full submission
abatacept (Orencia®) is not recommended for use within NHS Scotland, in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease-modifying anti-rheumatic drugs (DMARDs) including at least one tumour necrosis factor (TNF) inhibitor.
Abatacept (in combination with DMARDs) is significantly more efficacious than placebo (plus DMARDs) in rheumatoid arthritis patients who have previously failed anti-TNF therapy due to lack of efficacy. There are no data directly comparing abatacept with comparator products used in clinical practice. The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.
Download detailed advice133KB (PDF)
Medicine details
- Medicine name:
- abatacept 250mg powder for concentrate for solution (Orencia)
- SMC ID:
- 400/07
- Indication:
- in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have had an insufficient response or intolerance to other disease-modifying anti-rheumatic drugs (DMARDs) including at least one tumour necrosis factor (TNF) inhibitor.
- Pharmaceutical company
- Bristol-Myers Squibb Pharmaceuticals Ltd
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Full
- Status
- Superseded
- Date advice published
- 10 September 2007